Generated by AI
Prelude Therapeutics Incorporated is a clinical-stage precision oncology company focused on discovering and developing novel medicines for cancer patients with high unmet medical needs. Prelude Therapeutics Incorporated is advancing a pipeline of targeted therapies designed to address genetically defined cancers and other difficult-to-treat tumors. Its current programs include small-molecule candidates aimed at key cancer-driving mechanisms such as JAK2V617F, KAT6A, and SMARCA2, as well as approaches for myeloproliferative neoplasms, myelofibrosis, polycythemia vera, essential thrombocythemia, and breast cancer. The company’s work centers on precision medicine, using selective drug design to improve specificity against validated oncology targets. Prelude Therapeutics Incorporated operates as part of the biotechnology sector and plays a role in translating molecular biology insights into potential treatment options for underserved cancer populations.
Website175 Innovation Boulevard
Wilmington, DE, 19805
United States
The latest articles about PRLD.
Prelude Therapeutics (PRLD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Summary of Jul 28's posts. Generated by AI.
Summary of Dec 29's posts. Generated by AI.
Summary of Jul 28's posts. Generated by AI.
Investors talking about PRLD also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.